Lunai Bioworks Inc. 8-K

What Happened Lunai Bioworks Inc. (LNAI) announced in an 8-K that at a special meeting of stockholders on May 8, 2026, shareholders approved an amendment to the Company’s Certificate of Incorporation to effect a reverse stock split at a ratio to be chosen by the Board between 1-for-3 and 1-for-30. The company also received shareholder approval to adjourn the meeting if needed to solicit additional proxies. The 8-K, filed May 13, 2026, includes forward-looking statements about Nasdaq continued-listing compliance and the effects of the reverse split.

Key Details

• Reverse split range approved: 1-for-3 to 1-for-30; exact ratio to be determined by the Board.
• Proposal 1 (reverse split) vote: For 13,571,288; Against 1,153,415; Abstentions 61,177; Broker non-votes 0 — Approved.
• Proposal 2 (adjournment authority) vote: For 13,626,029; Against 1,091,528; Abstentions 68,323; Broker non-votes 0 — Approved.
• Filing notes risks that the reverse split may not result in compliance with Nasdaq’s bid-price rule and discloses standard forward-looking statement cautions.

Why It Matters A reverse stock split, if implemented, will reduce the number of outstanding shares and proportionally increase the per-share price, a common step companies take to try to meet Nasdaq minimum bid-price requirements. Approval gives the Board flexibility to choose a ratio within the approved range, but approval alone does not guarantee that Lunai will regain or maintain Nasdaq compliance. Investors should watch for the Board’s announced split ratio and any subsequent filings or notices from Nasdaq about listing status.